Physicians at the University of Illinois Hospital & Health Sciences System have cured 12 adult patients of sickle cell disease using a unique procedure for stem cell transplantation from healthy, tissue-matched siblings.
The transplants were the first to be performed outside of the National Institutes of Health campus in Maryland, where the procedure was developed. Physicians there have treated 30 patients, with an 87 percent success rate. The results of the phase I/II clinical trial at UI Health, in which 92 percent of treated patients were cured, are published online in the journal Biology of Blood & Marrow Transplantation.
The new technique eliminates the need for chemotherapy to prepare the patient to receive the transplanted cells and offers the prospect of cure for tens of thousands of adults suffering from sickle cell disease.
About 90 percent of the approximately 450 patients who have received stem cell transplants for sickle cell disease have been children. Chemotherapy has been considered too risky for adult patients, who are often more weakened than children by the disease.
“Adults with sickle cell disease are now living on average until about age 50 with blood transfusions and drugs to help with pain crises, but their quality of life can be very low,” says Dr. Damiano Rondelli, chief of hematology/oncology and director of the blood and marrow transplant program at UI Health, and corresponding author on the paper.
“Now, with this chemotherapy-free transplant, we are curing adults with sickle cell disease, and we see that their quality of life improves vastly within just one month of the transplant,” said Rondelli, who is also the Michael Reese Professor of Hematology in the UIC College of Medicine. “They are able to go back to school, go back to work, and can experience life without pain.”
Sickle cell disease is inherited. It primarily affects people of African descent, including about one in every 500 African Americans born in the U.S. The defect causes the oxygen-carrying red blood cells to be crescent shaped, like a sickle. The misshapen cells deliver less oxygen to the body’s tissues, causing severe pain and eventually stroke or organ damage.
Doctors have known for some time that bone marrow transplantation from a healthy donor can cure sickle cell disease. But few adults were transplanted because high-dose chemotherapy was needed to kill off the patients’ own blood-forming cells — and their entire immune system, to prevent rejection of the transplanted cells, leaving patients open to infection.
In the new procedure, patients receive immunosuppressive drugs just before the transplant, along with a very low dose of total body irradiation — a treatment much less harsh and with fewer potentially serious side effects than chemotherapy.
Next, donor cells from a healthy and tissue-matched sibling are transfused into the patient. Stem cells from the donor produce healthy new blood cells in the patient, eventually in sufficient quantity to eliminate symptoms. In many cases, sickle cells can no longer be detected. Patients must continue to take immunosuppressant drugs for at least a year.
In the reported trial, the researchers transplanted 13 patients, 17 to 40 years of age, with a stem cell preparation from the blood of a tissue-matched sibling. Healthy sibling donor-candidates and patients were tested for human leukocyte antigen, a set of markers found on cells in the body. Ten of these HLA markers must match between the donor and the recipient for the transplant to have the best chance of evading rejection.
In a further advance of the NIH procedure, physicians at UI Health successfully transplanted two patients with cells from siblings who matched for HLA but had a different blood type.
In all 13 patients, the transplanted cells successfully took up residence in the marrow and produced healthy red blood cells. One patient who failed to follow the post-transplant therapy regimen reverted to the original sickle cell condition.
None of the patients experienced graft-versus-host disease, a condition where immune cells originating from the donor attack the recipient’s body.
One year after transplantation, the 12 successfully transplanted patients had normal hemoglobin concentrations in their blood and better cardiopulmonary function. They reported less pain and improved health and vitality.
Four of the patients were able to stop post-transplantation immunotherapy without transplant rejection or other complications.
The Latest on: Sickle cell disease
via Google News
The Latest on: Sickle cell disease
- Novel Sickle Cell Disease Causes Radical Results In End Of Life Patientson November 30, 2019 at 6:41 am
This week the FDA approved a novel treatment for sickle cell disease, a serious and sometimes deadly disease that affects around 100,000 Americans. The treatment was found to exceptionally improve the ...
- FDA Approves Oxbryta for Treatment of Sickle Cell Diseaseon November 26, 2019 at 9:46 pm
TUESDAY, Nov. 26, 2019 (HealthDay News) -- Oxbryta (voxelotor) has been granted accelerated approval for the treatment of sickle cell disease in patients ages 12 years and older, the U.S. Food and ...
- A new Sickle cell disease drug holds much promise but most sufferers won’t be able to afford iton November 26, 2019 at 4:04 pm
The regulatory approval of a groundbreaking new Sickle cell disease drug in the United States by the Food and Drugs Administration (FDA) sparked off plenty of hope and optimism earlier this month and ...
- New Drugs Emerge to Treat Sickle Cell Diseaseon November 25, 2019 at 1:28 pm
The U.S. Food and Drug Administration approved a new drug for sickle cell disease Monday, adding to a new wave of treatments that promise relief from the life-threatening blood disorder that largely ...
- Global Blood secures FDA approval for new pill to treat sickle cell diseaseon November 25, 2019 at 1:16 pm
The Food and Drug Administration on Monday approved a once-daily pill for sickle cell disease that works in an entirely new way — by boosting hemoglobin, the oxygen-carrying molecule found in red ...
- FDA approves Global Blood Therapeutics sickle cell disease drugon November 25, 2019 at 12:56 pm
Nov 25 (Reuters) - The U.S. Food and Drug Administration said on Monday it approved a drug from Global Blood Therapeutics Inc to treat sickle cell disease in adults and children 12 years or older. © ...
- FDA approves Global Blood Therapeutics's sickle cell disease drugon November 25, 2019 at 12:56 pm
The U.S. Food and Drug Administration said on Monday it had approved Global Blood Therapeutics's drug, Oxbryta, to treat sickle cell disease in adults and pediatric patients aged 12 years or older.
- Global Blood Therapeutics scores FDA nod for Oxbryta, forecasts 'paradigm shift' in sickle cell diseaseon November 25, 2019 at 12:26 pm
Another day, another early FDA nod. Global Blood Therapeutics has its first drug approval, and it’s one that’ll bring a “paradigm shift” in how patients with sickle cell disease are treated, execs say ...
- FDA Approves Oxbryta(TM) (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Diseaseon November 25, 2019 at 12:03 pm
a new class of therapy Oxbryta broadly indicated for the treatment of sickle cell disease in adults and children 12 years of age and older1 Approval comes three months ahead of FDA's priority review ...
- Global Sickle Cell Disease Treatment Market 2019-2023| Evolving Opportunities with ADDMEDICA and Bristol-Myers Squibb | Technavioon November 22, 2019 at 4:01 pm
The global sickle cell disease treatment market is poised to grow by USD 1.85 billion during 2019-2023, progressing at a CAGR of over 11% during the forecast period. Request Free Sample Pages This ...
via Bing News